Study shows promise of new anti-KRAS drug for pancreatic cancer
A small molecule inhibitor that attacks the difficult to target, cancer-causing gene mutation KRAS, found in nearly 30 percent of all human tumors, successfully shrunk tumors or stopped cancer growth in preclinical models of pancreatic cancer, researchers showed.
Materials provided by University of Pennsylvania School of Medicine. Note: Content may be edited for style and length.
Source link aaaaa